BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Affimed Therapeutics AG 

Technologiepark
Im Neuenheimer Feld 582
Heidelberg    69120   Germany
Phone: 49-6221-65307-0 Fax: 49-6221-65307-77


SEARCH JOBS




Industry
Biotechnology






 Company News
Affimed Therapeutics AG (AFMD) Presents Final Data For AFM13 Phase 1 Trial At American Society of Hematology 12/8/2014 8:06:44 AM
Affimed Therapeutics AG (AFMD) To Present At The Jefferies and Co. Global Healthcare Conference - London 11/12/2014 10:10:57 AM
Affimed Therapeutics AG (AFMD) Announces Third Quarter 2014 Financial Results Conference Call 11/11/2014 8:44:42 AM
Affimed Therapeutics AG (AFMD) Announces Closing Of Initial Public Offering 9/18/2014 7:48:47 AM
Affimed Therapeutics AG (AFMD) Prices IPO At $7, Below The Range 9/12/2014 7:07:32 AM
Immuno-Oncology Biotech Affimed Therapeutics AG Files For $75 Million IPO 6/30/2014 7:06:04 AM
Affimed Therapeutics AG Highlights Further Data On AFM13, A Bispecific CD30/CD16A TandAb in Development To Treat Hodgkin Lymphoma, At The 2014 American Association for Cancer Research Annual Meeting 4/10/2014 7:49:05 AM
The Leukemia & Lymphoma Society and Affimed Therapeutics AG Partner to Advance AFM13 in a Phase 2 Trial for Refractory and/or Relapsed Hodgkin Lymphoma Patients 9/16/2013 11:00:04 AM
Affimed Therapeutics AG Reports Phase 1 Clinical Data for Its Immunotherapy AFM13 in Relapsing/Refractory Hodgkin Lymphoma Patients 6/24/2013 11:28:16 AM
Affimed Therapeutics AG Raises $20 Million in a Series D Financing Round 10/8/2012 7:38:13 AM
123